AstraZeneca Is Selling Its Antibiotics Business to Pfizer

Pharmaceutical company AstraZeneca AZNCF-1.41%said it had agreed to sell its small molecule antibiotics business to PfizerPFE-0.23% in a deal that could reach more than $1.5 billion.

The portfolio includes approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development, it said.

Pfizer will pay $550 million upon completion and a further unconditional $175 million in January 2019, AstraZeneca said, plus up to $250 million in milestones, up to $600 million in sales-related payments and recurring, double-digit royalties on future sales of Zavicefta and ATM-AVI in certain markets.

The British company said the agreement did not impact its financial guidance for 2016.

Summary: The deal could fetch more than $1.5 billion.
Pharmaceutical company AstraZeneca AZNCF -1.41% said it had agreed to sell its small molecule antibiotics business to Pfizer PFE -0.23% in a deal that could reach more than $1.5 billion.

The portfolio includes approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development, it said.

Pfizer will pay $550 million upon completion and a further unconditional $175 million in January 2019, AstraZeneca said, plus up to $250 million in milestones, up to $600 million in sales-related payments and recurring, double-digit royalties on future sales of Zavicefta and ATM-AVI in certain markets.

Consider the life of a chef on the road. Even when they’re not doing “research” for an upcoming project—trips that are essentially designed for overeating and drinking—they’re still likely seeking the best of what got them into the industry in the first place: damn good food.

The proliferation of low-cost airlines flying out of the U.S. means that it’s now possible to hop to Europe for as low as half the price charged by major carriers, the New York Times writes. But there’s always a trade-off — and it pays to comparison-shop, according to the publication.

Featured Contributors

Chasing snake oil and fad gurus is harmless until your journey of personal discovery becomes a platform for prescribing therapies to complete strangers. Any reasonably diligent venture capital partner should be weighing the risks.

Shkreli — who famously insulted members of Congress earlier this year but refused to testify officially over his own decision to increase the price of a life-saving pill — is now hopping at the chance to defend generic drug manufacturer Mylan.
He may even have opened the door to testify before the House Committee on Oversight and Government Reform, where he previously cited his Fifth Amendment's right to avoid incriminating himself.
"Any chance i can come through this time and actually testify?" he tweeted Thursday in a post directed at the committee's Democrats.
All of this now paves an unlikely new friendship between Shkreli and Mylan CEO Heather Bresch.
Heather Bresch created about $15 billion in value for Mylan in the seven years since she stepped up as president of the company. A big part of that value add came from her talent for repackaging off-the-shelf drugs into bona fide blockbusters.

Donald Trump is talking about Hillary Clinton’s health, as are two doctors who havenever evaluated Clinton. They have apparently diagnosed her with all kinds of ailments using the long disproven Fox-Drudge equation.
This attention on Clinton has renewed some interest in the letter Donald Trump released last year from his personal physician.

Even as doctors enter a medical field with more paying patients under the Affordable Care Act and unprecedented numbers of job opportunities, 25 percent of “newly trained physicians” would still choose another field if they could, according to a new analysis.